KEYNOTE-A31, NCT04130542: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy |
|
|
| Active, not recruiting | 1 | 276 | US | LVGN6051, KEYTRUDA® (pembrolizumab) | Lyvgen Biopharma Holdings Limited, Merck Sharp & Dohme LLC | Cancer | 12/25 | 12/25 | | |